Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have been assigned a consensus rating of “Hold” from the fourteen brokerages that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $26.56.

Several research analysts have recently weighed in on the company. Zacks Investment Research downgraded Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Friday. Cowen reiterated a “hold” rating and set a $25.00 price target on shares of Myriad Genetics in a research note on Sunday, September 17th. Stephens reiterated an “overweight” rating and set a $40.00 price target (up previously from $36.00) on shares of Myriad Genetics in a research note on Friday, September 22nd. ValuEngine downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, Leerink Swann restated a “market perform” rating and issued a $31.00 target price on shares of Myriad Genetics in a research note on Monday, October 2nd.

Myriad Genetics (NASDAQ MYGN) opened at $33.47 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. The firm has a market capitalization of $2,320.00, a price-to-earnings ratio of 30.71, a PEG ratio of 2.13 and a beta of 0.25. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $37.30.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.05. The company had revenue of $190.20 million during the quarter, compared to the consensus estimate of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.23 EPS. research analysts forecast that Myriad Genetics will post 1.05 earnings per share for the current fiscal year.

In other news, Director Walter Phd Gilbert sold 7,500 shares of Myriad Genetics stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $33.19, for a total transaction of $248,925.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander Ford sold 3,031 shares of Myriad Genetics stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $31.64, for a total value of $95,900.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,531 shares of company stock valued at $545,826. 6.70% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of MYGN. Aperio Group LLC boosted its position in shares of Myriad Genetics by 4.6% during the 2nd quarter. Aperio Group LLC now owns 12,129 shares of the company’s stock valued at $313,000 after acquiring an additional 534 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Myriad Genetics by 3.1% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 16,080 shares of the company’s stock valued at $416,000 after acquiring an additional 490 shares during the last quarter. Great West Life Assurance Co. Can boosted its position in shares of Myriad Genetics by 3.3% during the 2nd quarter. Great West Life Assurance Co. Can now owns 100,694 shares of the company’s stock valued at $2,598,000 after acquiring an additional 3,180 shares during the last quarter. CIBC Asset Management Inc bought a new stake in shares of Myriad Genetics during the 2nd quarter valued at about $218,000. Finally, Pictet Asset Management Ltd. boosted its position in shares of Myriad Genetics by 8.1% during the 2nd quarter. Pictet Asset Management Ltd. now owns 127,396 shares of the company’s stock valued at $2,593,000 after acquiring an additional 9,600 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.watchlistnews.com/myriad-genetics-inc-mygn-given-average-rating-of-hold-by-analysts/1770767.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.